Die Psybrary ™: 12 Abenteuergeschichten, bei denen Sie selbst eine von Millionen Endungen wählen können
Ryan Allway March 12th, 2021 German, Psychedelics Die Psybrary™ von MagicMed ist eine bemerkenswerte und beeindruckende Leistung, die mehr als geschätzten 125 Millionen Derivaten bis zu deren Patenterteilung Patentschutz bieten könnte. Während 125 Millionen Derivate eine große Zahl ist, sollten dabei zwei Dinge klargestellt werden. Erstens bedeutet diese Zahl... Read more
Tryp Therapeutics Announces Application to List on OTCQB
Ryan Allway March 4th, 2021 Psychedelics, Top News Tryp Therapeutics (CSE: TRYP) (“Tryp” or the “Company”) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market... Read more
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
Ryan Allway March 4th, 2021 Psychedelics Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes... Read more
Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research
Ryan Allway March 4th, 2021 Psychedelics Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada’s Controlled Drugs and Substances Act that enhance the Company’s ability to lead psychedelics research... Read more
Psyence Group Launches its Functional Mushroom Brand, “GOODMIND” Makes Board Changes
Ryan Allway March 4th, 2021 Psychedelics Psyence Group Inc., a leading platform in naturally derived psychedelic therapy and the development and commercialization of related technologies and products (“Psyence”), is pleased to announce it has launched its functional mushroom brand, “GOODMIND”, through a South African-based special purpose vehicle (“SPV”) called... Read more
PsyBio Therapeutics Announces Retention of Market Maker
Ryan Allway March 4th, 2021 Psychedelics PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX Venture Exchange (“TSXV”), it has retained Generation IACP Inc. (“Generation”) to provide market making services with... Read more
Cybin Inc. Announces Uplisting to OTCQB Venture Market
Ryan Allway March 3rd, 2021 Psychedelics Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). Cybin will commence trading on the OTCQB with the market open on March... Read more
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
Ryan Allway March 3rd, 2021 Psychedelics Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of... Read more
Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to Advisory Board
Ryan Allway March 3rd, 2021 Psychedelics Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board. Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart... Read more
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research
Ryan Allway March 3rd, 2021 Psychedelics Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )